This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spellberg, B. J.
Right arrow Articles by Edwards, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spellberg, B. J.
Right arrow Articles by Edwards, J. E., Jr.

 Previous Article  |  Next Article 

Infection and Immunity, September 2005, p. 6191-6193, Vol. 73, No. 9
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.9.6191-6193.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

The Anti-Candida albicans Vaccine Composed of the Recombinant N Terminus of Als1p Reduces Fungal Burden and Improves Survival in Both Immunocompetent and Immunocompromised Mice

Brad J. Spellberg,1,2* Ashraf S. Ibrahim,1,2 Valentina Avenissian,1 Scott G. Filler,1,2 Carter L. Myers,1 Yue Fu,1,2 and John E. Edwards Jr.1,2

Division of Infectious Diseases, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, Torrance, California,1 The David Geffen School of Medicine at UCLA, Los Angeles, California2

Received 14 March 2005/ Accepted 11 April 2005

We have previously shown that intraperitoneal vaccination with the recombinant N terminus of Als1p (rAls1p-N) modestly improves survival during murine disseminated candidiasis. We now report marked efficacy with subcutaneous rAls1p-N vaccination. Efficacy is retained in neutropenic and corticosteroid-treated mice. The rAls1p-N vaccine is a promising candidate for the prevention of invasive candidiasis.

* Corresponding author: Division of Infectious Diseases, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, 1124 W. Carson St., Torrance, CA 90502. Phone: (310) 222-5381. Fax: (310) 782-2016. E-mail: bspellberg{at}labiomed.org.

Editor: T. R. Kozel

Infection and Immunity, September 2005, p. 6191-6193, Vol. 73, No. 9
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.9.6191-6193.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Saville, S. P., Lazzell, A. L., Chaturvedi, A. K., Monteagudo, C., Lopez-Ribot, J. L. (2009). Efficacy of a Genetically Engineered Candida albicans tet-NRG1 Strain as an Experimental Live Attenuated Vaccine against Hematogenously Disseminated Candidiasis. CVI 16: 430-432 [Abstract] [Full Text]  
  • Spellberg, B., Ibrahim, A. S., Yeaman, M. R., Lin, L., Fu, Y., Avanesian, V., Bayer, A. S., Filler, S. G., Lipke, P., Otoo, H., Edwards, J. E. Jr. (2008). The Antifungal Vaccine Derived from the Recombinant N Terminus of Als3p Protects Mice against the Bacterium Staphylococcus aureus. Infect. Immun. 76: 4574-4580 [Abstract] [Full Text]  
  • Lin, L., Ibrahim, A. S., Avanesian, V., Edwards, J. E. Jr., Fu, Y., Baquir, B., Taub, R., Spellberg, B. (2008). Considerable Differences in Vaccine Immunogenicities and Efficacies Related to the Diluent Used for Aluminum Hydroxide Adjuvant. CVI 15: 582-584 [Abstract] [Full Text]  
  • Brena, S., Omaetxebarria, M. J., Elguezabal, N., Cabezas, J., Moragues, M. D., Ponton, J. (2007). Fungicidal Monoclonal Antibody C7 Binds to Candida albicans Als3. Infect. Immun. 75: 3680-3682 [Abstract] [Full Text]  
  • Richard, M. L., Plaine, A. (2007). Comprehensive Analysis of Glycosylphosphatidylinositol-Anchored Proteins in Candida albicans. Eukaryot Cell 6: 119-133 [Full Text]  
  • Rauceo, J. M., De Armond, R., Otoo, H., Kahn, P. C., Klotz, S. A., Gaur, N. K., Lipke, P. N. (2006). Threonine-Rich Repeats Increase Fibronectin Binding in the Candida albicans Adhesin Als5p. Eukaryot Cell 5: 1664-1673 [Abstract] [Full Text]  
  • Ibrahim, A. S., Spellberg, B. J., Avanesian, V., Fu, Y., Edwards, J. E. Jr. (2006). The Anti-Candida Vaccine Based on the Recombinant N-Terminal Domain of Als1p Is Broadly Active against Disseminated Candidiasis.. Infect. Immun. 74: 3039-3041 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»